Kontro Lab

This paper reports that authors identify molecular patterns linked to primary resistance to VEN–HMA therapy, including a higher BCL‑XL/BCL‑2 ratio and frequent TP53 mutations. These findings point to potential therapeutic strategies worth exploring Read more in depth 👉bit.ly/3Lllpo9

Our latest @Hemasphere_EHA study from @FIMM_UH defines key signatures of #venetoclax + hypomethylating agent #resistance in #AML and highlights strategies for targeting resistant disease. Read more: doi.org/10.1002/hem3.7…

Data presented at #ESMO25 by Dr Mika Kontro on the Macrophage reprogrammer #bexmarilimab plus azacitidine in myelodysplastic syndrome (BEXMAB) @myESMO @OncoAlert @Daver_Leukemia @Dr_AmerZeidan

New findings from our VenEx trial in #AML: venetoclax resistance linked to altered apoptosis & PRAME overexpression. Exploring PRAME-targeted immunotherapy + apoptosis modulators. Grateful for Jane and Aatos Erkko Foundation support to advance this research. #JAES

1/4 Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial New study by @LabKontro and colleagues – study highlights 👇

Ex vivo venetoclax sensitivity identified treatment responders and correlated with improved outcomes and prolonged survival. Groundbreaking results from the VenEx trial with the Finnish AML Group, @helsinkiuni and @FIMM_UH published now in @BloodJournal

Drug sensitivity testing on leukemia cells can predict how patients with acute myeloid leukemia (AML) will respond to a new combination therapy. New @LabKontro results allow treatments to be tailored to those who are most likely to benefit. 📰@HUS_fi: hus.fi/en/newsroom/dr…

Leukemiasolujen lääkeherkkyystestauksella voidaan ennustaa akuuttia myelooista leukemiaa sairastavien potilaiden hoitovaste uudelle lääkeyhdistelmälle. @LabKontro tulokset mahdollistavat hoidon kohdentamisen siitä eniten hyötyville potilaille. 📰@HUS_fi: hus.fi/ajankohtaista/…

Dr. Mika Kontro from @KontroLab discussed the latest advances in functional screening during the Multi-Omics Driven Precision Hematology Scientific Symposia at #ASH23. The VenEx trial indicates the efficacy of ex vivo venetoclax testing for predicting VEN+AZA responses in AML.

Meet our K. Albin Johansson Cancer Researcher @hkuusanm. Heikki has a versatile background in translational laboratory studies and focuses now on novel treatments for acute myeloid leukemia in @LabKontro. Read more 👇syopainstituutti.com/researcher-pos…

A clinical trial performed in Finland has shown that a drug sensitivity test performed on patient's own cells in laboratory conditions predicts patient's response to a new effective leukemia drug, venetoclax. The study was led by Mika Kontro & @hkuusanm. helsinki.fi/en/hilife-hels…

1/ Excited to share our study with @ollidufva suggesting venetoclax resistance and BCL-XL dependence in erythroid/megakaryoblastic AML @BloodJournal doi.org/10.1182/blood.…

Our newest paper "Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia" is now published and accessible @Haematologica haematologica.org/article/view/h…

Ex vivo venetoclax sensitivity predicts responses in both de novo and s/R/R AML patients @LabKontro #ASH22

Excellent talk by @josephsaad95 on NAMPT inhibitors in AML with monosomy 7/del(7q) yesterday at #ASH22!

Ex vivo drug sensitivity testing predicts venetoclax+azacitidine treatment responses in AML. VenEx trial interim results presented at #ASH21